Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden

被引：9
|
作者：
Hammond, John [1 ]
Thompson, Alexis A. [4 ,5 ]
Fogel, Mark A. [2 ]
Hammond, Katherine [4 ]
Kokroko, Jolene [1 ]
Kwiatkowski, Janet L. [1 ,3 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Cardiol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2019年 / 41卷 / 01期
关键词：
thalassemia; iron overload; deferasirox; deferiprone; MYOCARDIAL IRON; DEFERIPRONE THERAPY; DEFERASIROX; SAFETY; DEFEROXAMINE; TRIAL; RISK;
D O I：
10.1097/MPH.0000000000001269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload. Enrollment proved difficult. Nine patients (median age, 27.4 y; ferritin, 4965 ng/mL; liver iron concentration, 28.5 mg/g dry weight; cardiac T2*, 13.3 ms) received treatment. Two were withdrawn for treatment-related adverse effects. Arthralgia (4 patients) and gastrointestinal symptoms (5 patients) were common; no episodes of neutropenia/agranulocytosis occurred. Adherence difficulties were common. Of 6 patients with 12 to 18 months follow-up, 3 showed improvement in cardiac T2* and 2 in liver iron. Combination oral chelation may be effective but adverse effects and adherence challenges may limit efficacy.
引用
收藏
页码：E47 / E50
页数：4
相关论文
共 50 条
  • [1] Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
    Origa, Raffaella
    Cinus, Monia
    Pilia, Maria Paola
    Gianesin, Barbara
    Zappu, Antonietta
    Orecchia, Valeria
    Clemente, Maria Grazia
    Pitturru, Carla
    Denotti, Anna Rita
    Corongiu, Francesco
    Piras, Simona
    Barella, Susanna
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [2] Current recommendations for chelation for transfusion-dependent thalassemia
    Kwiatkowski, Janet L.
    COOLEY'S ANEMIA, 2016, 1368 : 107 - 114
  • [3] Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni, Gian Luca
    Kattamis, Antonis
    Kuo, Kevin H. M.
    Maggio, Aurelio
    Sheth, Sujit
    Taher, Ali T.
    Viprakasit, Vip
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [4] Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients
    Bordbar, Mohammadreza
    Haghpanah, Sezaneh
    Zekavat, Omid Reza
    Saki, Forough
    Bazrafshan, Asghar
    Bozorgi, Haleh
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (11) : 997 - 1003
  • [5] Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia
    Jamuar, Saumya S.
    Lai, Angeline H. M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (05) : 299 - 307
  • [6] Practice of iron chelation therapy for transfusion-dependent thalassemia in Southeast Asia
    Azman, Nurul Fatihah
    Abdullah, Wan-Zaidah
    Mohamad, Norsarwany
    Bahar, Rosnah
    Johan, Muhammad Farid
    Diana, R.
    Sarifah, Binti Hanafi
    Yusoff, Surini
    Nasir, Ariffin
    Othman, Azizah
    Sukeri, Surianti
    Ibrahim, Mohd Ismail
    Hussein, Adil
    Hassan, Rozita
    Yahya, Padillah
    Hassan, Rosline
    Zilfalil, Bin Alwi
    ASIAN BIOMEDICINE, 2016, 10 (06) : 537 - 547
  • [7] Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators' era
    Pines, Morgan
    Kleinert, Dorothy
    Thomas, Charlene
    Mensah, Cheryl
    Musallam, Khaled M.
    Sheth, Sujit
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5229 - 5234
  • [8] Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia
    Jamuar, Saumya Shekhar
    Lai, Angeline Hwei Meeng
    Tan, Ah Moy
    Chan, Mei Yoke
    Tan, Ee Shien
    Ng, Ivy Swee Lian
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2011, 47 (11) : 812 - 817
  • [9] Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications
    Farmaki, Kallistheni
    Tzoumari, Ioanna
    Pappa, Christina
    BLOOD CELLS MOLECULES AND DISEASES, 2011, 47 (01) : 33 - 40
  • [10] Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data
    Chadha, Amitoj Singh
    Mohammad, Abaan Ul Haq Khazi
    Nadakuditi, Naveen Kanth Dhami
    Agrawal, Surbhi
    Alex, Kenson Sam
    Naik, Namratha S.
    Raj, John Michael
    Prakash, Anand
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025, 41 (01) : 167 - 170
12345